help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montine, T. J.
Right arrow Articles by Morrow, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montine, T. J.
Right arrow Articles by Morrow, J. D.
(American Journal of Pathology. 2005;166:1283-1289.)
© 2005 American Society for Investigative Pathology

Review

Fatty Acid Oxidation in the Pathogenesis of Alzheimer’s Disease

Thomas J. Montine* and Jason D. Morrow{dagger}

From the Department of Pathology,* University of Washington, Seattle, Washington; and the Departments of Medicine and Pharmacology,{dagger} Vanderbilt University, Nashville, Tennessee

Abstract

Alzheimer’s disease (AD) is the most common dementing illness of the elderly and is a mounting public health problem. Pharmacoepidemiological data, analytical data from human tissue and body fluids, and mechanistic data mostly from murine models all have implicated oxidation products of two fatty acids, arachidonic acid (AA) and docosahexaenoic acid (DHA), in the pathogenesis of neurodegeneration. Here we review the biochemistry of AA and DHA oxidation, both enzyme-catalyzed and free radical mediated, and summarize those studies that have investigated these oxidation products as effectors of neurodegeneration and biomarkers of AD. Given the evolving appreciation for toxicity associated with current pharmaceuticals used to block AA and DHA oxidation, we close by speculating on likely areas of future research directed at suppressing this facet of neurodegeneration. If successful, these interventions are unlikely to cure AD, but may check its explosive growth and hopefully reduce its incidence and prevalence in the elderly.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
E. S. Musiek, J. D. Brooks, M. Joo, E. Brunoldi, A. Porta, G. Zanoni, G. Vidari, T. S. Blackwell, T. J. Montine, G. L. Milne, et al.
Electrophilic Cyclopentenone Neuroprostanes Are Anti-inflammatory Mediators Formed from the Peroxidation of the {omega}-3 Polyunsaturated Fatty Acid Docosahexaenoic Acid
J. Biol. Chem., July 18, 2008; 283(29): 19927 - 19935.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Yin, L. Gao, H.-H. Tai, L. J. Murphey, N. A. Porter, and J. D. Morrow
Urinary Prostaglandin F2{alpha} Is Generated from the Isoprostane Pathway and Not the Cyclooxygenase in Humans
J. Biol. Chem., January 5, 2007; 282(1): 329 - 336.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society for Investigative Pathology.